Concepts (86)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proto-Oncogene Proteins c-met | 5 | 2019 | 200 | 0.850 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2021 | 162 | 0.690 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 307 | 0.670 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 177 | 0.640 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 603 | 0.570 |
Why?
|
| Lung Neoplasms | 5 | 2021 | 2336 | 0.440 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 1111 | 0.400 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 340 | 0.370 |
Why?
|
| ErbB Receptors | 2 | 2012 | 496 | 0.350 |
Why?
|
| Mutation | 4 | 2019 | 4097 | 0.340 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 2406 | 0.310 |
Why?
|
| Ovarian Neoplasms | 1 | 2012 | 759 | 0.260 |
Why?
|
| Neoplasms | 2 | 2019 | 3009 | 0.250 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2012 | 78 | 0.180 |
Why?
|
| Isothiocyanates | 2 | 2012 | 7 | 0.180 |
Why?
|
| Carcinogenesis | 1 | 2021 | 207 | 0.160 |
Why?
|
| Apoptosis | 3 | 2012 | 1718 | 0.120 |
Why?
|
| Rhodamines | 1 | 2012 | 18 | 0.110 |
Why?
|
| Annexin A5 | 1 | 2012 | 20 | 0.110 |
Why?
|
| Cell Line, Tumor | 4 | 2012 | 2538 | 0.110 |
Why?
|
| Indoles | 3 | 2009 | 310 | 0.110 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 397 | 0.100 |
Why?
|
| Mice, Nude | 1 | 2012 | 814 | 0.090 |
Why?
|
| Signal Transduction | 1 | 2021 | 3368 | 0.090 |
Why?
|
| PAX5 Transcription Factor | 1 | 2009 | 32 | 0.080 |
Why?
|
| Vulva | 1 | 2008 | 23 | 0.080 |
Why?
|
| Paxillin | 1 | 2008 | 59 | 0.080 |
Why?
|
| Humans | 8 | 2021 | 88611 | 0.080 |
Why?
|
| Protein Kinase C | 1 | 2008 | 268 | 0.070 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2009 | 102 | 0.070 |
Why?
|
| G2 Phase | 1 | 2006 | 34 | 0.070 |
Why?
|
| Pleural Neoplasms | 1 | 2008 | 197 | 0.070 |
Why?
|
| Mesothelioma | 1 | 2008 | 321 | 0.060 |
Why?
|
| Cell Division | 1 | 2006 | 696 | 0.060 |
Why?
|
| DNA Damage | 1 | 2006 | 371 | 0.060 |
Why?
|
| Mice | 3 | 2012 | 11710 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2006 | 659 | 0.050 |
Why?
|
| Animals | 4 | 2012 | 27233 | 0.040 |
Why?
|
| Gene Dosage | 2 | 2009 | 208 | 0.040 |
Why?
|
| DNA Mutational Analysis | 2 | 2009 | 531 | 0.040 |
Why?
|
| Piperazines | 2 | 2009 | 280 | 0.040 |
Why?
|
| Cell Proliferation | 3 | 2008 | 1647 | 0.040 |
Why?
|
| Sulfonamides | 2 | 2009 | 318 | 0.040 |
Why?
|
| RNA Interference | 2 | 2008 | 378 | 0.040 |
Why?
|
| Female | 3 | 2012 | 45759 | 0.030 |
Why?
|
| Semaphorins | 1 | 2009 | 17 | 0.020 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2009 | 34 | 0.020 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2009 | 24 | 0.020 |
Why?
|
| Phorbol Esters | 1 | 2008 | 22 | 0.020 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2009 | 29 | 0.020 |
Why?
|
| Paired Box Transcription Factors | 1 | 2009 | 52 | 0.020 |
Why?
|
| Protein Kinase C beta | 1 | 2008 | 14 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2008 | 64 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 274 | 0.020 |
Why?
|
| Genes, erbB-1 | 1 | 2008 | 16 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 247 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2009 | 354 | 0.020 |
Why?
|
| Exons | 1 | 2009 | 452 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2008 | 182 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 307 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 927 | 0.020 |
Why?
|
| Cyclin B | 1 | 2006 | 18 | 0.020 |
Why?
|
| Cyclin B1 | 1 | 2006 | 18 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2009 | 559 | 0.020 |
Why?
|
| CDC2 Protein Kinase | 1 | 2006 | 46 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 196 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2009 | 594 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 646 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2006 | 70 | 0.020 |
Why?
|
| Nicotine | 1 | 2008 | 199 | 0.020 |
Why?
|
| Cisplatin | 1 | 2008 | 616 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2008 | 741 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 575 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2008 | 1129 | 0.020 |
Why?
|
| Caenorhabditis elegans | 1 | 2008 | 229 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2009 | 1295 | 0.020 |
Why?
|
| Cell Movement | 1 | 2008 | 784 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 1867 | 0.020 |
Why?
|
| Survival Rate | 1 | 2008 | 1883 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2009 | 1256 | 0.010 |
Why?
|
| Prognosis | 1 | 2009 | 3750 | 0.010 |
Why?
|
| Phenotype | 1 | 2008 | 2435 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 6723 | 0.010 |
Why?
|
| Male | 2 | 2009 | 42012 | 0.010 |
Why?
|
| Aged | 1 | 2009 | 18932 | 0.010 |
Why?
|
| Middle Aged | 1 | 2009 | 25699 | 0.010 |
Why?
|